Optimal blood pressure for patients with end-stage renal disease following coronary interventions.
Ya-Ling YangSu-Chan ChenCheng-Hsueh WuShao-Sung HuangWan Leong ChanShing-Jong LinChia-Yu ChouJaw-Wen ChenPan Ju-PinMin-Ji CharngYing-Hwa ChenTao-Cheng WuTse-Min LuPai-Feng HsuPo-Hsun HuangHao-Min ChengChin-Chou HuangShih-Hsien SungYenn-Jiang LinHsin-Bang LeuPublished in: Journal of clinical hypertension (Greenwich, Conn.) (2021)
Hypertension is a frequent manifestation of chronic kidney disease but the ideal blood pressure (BP) target in patients with coronary artery disease (CAD) with end-stage renal disease (ESRD) (eGFR < 15 ml/min/1.73m2 ) still unclear. The authors aimed to investigate the ideal achieved BP in ESRD patients with CAD after coronary intervention. Five hundred and seventy-five ESRD patients who had undergone percutaneous coronary interventions (PCIs) were enrolled and their clinical outcomes were analyzed according to the category of systolic BP (SBP) and diastolic BP (DBP) achieved. The clinical outcomes included major cardiovascular events (MACE) and MACE plus hospitalization for congestive heart failure (total cardiovascular (CV) event).The mean systolic BP was 135.0 ± 24.7 mm Hg and the mean diastolic BP was 70.7 ± 13.1 mm Hg. Systolic BP 140-149 mm Hg and diastolic BP 80-89 mm Hg had the lowest MACE (11.0%; 13.2%) and total CV event (23.3%; 21.1%). Patients with systolic BP < 120 mm Hg had a higher risk of MACE (HR: 2.01; 95% CI: 1.17-3.46, p = .008) than those with systolic BP 140-149 mm Hg. Patients with systolic BP ≥ 160 mm Hg (HR: 1.84; 95% CI, 3.27-1.04, p = .04) and diastolic blood BP ≥ 90 mm Hg (HR: 2.19; 95% CI: 1.15-4.16, p = .02) had a higher risk of total CV event rate when compared to those with systolic BP 140-149 mm Hg and diastolic BP 80-89 mm Hg. A J-shaped association between systolic (140-149 mm Hg) and diastolic (80-89 mm Hg) BP and decreased cardiovascular events for CAD was found in patients with ESRD after undergoing PCI in non-Western population.
Keyphrases
- blood pressure
- left ventricular
- end stage renal disease
- chronic kidney disease
- coronary artery disease
- heart failure
- cardiovascular events
- fluorescent probe
- hypertensive patients
- peritoneal dialysis
- heart rate
- aqueous solution
- living cells
- coronary artery
- cardiovascular disease
- randomized controlled trial
- percutaneous coronary intervention
- small cell lung cancer
- aortic stenosis
- cardiac resynchronization therapy
- blood glucose
- skeletal muscle
- metabolic syndrome
- type diabetes
- antiplatelet therapy
- atrial fibrillation
- epidermal growth factor receptor
- acute coronary syndrome
- transcatheter aortic valve replacement
- arterial hypertension